Search clinical trials for: Medi-524

Total 2442 results

MedImmune LLC

Withdrawn

A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants

Wheezing
MedImmune LLC

Completed

Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children

Respiratory Syncytial Virus Infections

United States, France, Spain, Denmark, Australia, New Zealand, Israel, United Kingdom, Italy, Sweden, Germany, Hungary, Chile, Argentina, Austria, Brazil, Bulgaria, Canada, Czech Republic, Greece, Iceland, Poland, Russian Federation, ...
MedImmune LLC

Completed

Open-Label, Dose-Escalation Study of 2 to 5 IM Doses of MEDI-524 at 3 mg/kg or 15 mg/kg; Children to be Followed for 90 Days After Their Last Dose of MEDI-524

Respiratory Syncytial Virus Infections

Chile, Argentina
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Asthma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Dose Subcutaneous Administration of MEDI-528

Healthy

United States
MedImmune LLC

Completed

Phase I Trial of Weekly MEDI-522 in Patients With Refractory Solid Tumors

Cancer

France
MedImmune LLC

Completed

MEDI-524 (Motavizumab) for the Prevention of Respiratory Sycytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States

Healthy

United States
MedImmune LLC

Terminated

A Study to Evaluate a Single Intramuscular Dose of Motavizumab to Treat Children With Respiratory Syncytial Virus (RSV) Illness

Participants Less Than 12 Months of Age With RSV Illness

United States
MedImmune LLC

Completed

A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

RSV Illness in ≤12 Months of Participants

United States, Chile, New Zealand, Australia, Panama
MedImmune LLC

Completed

Study to Evaluate MEDI-534 in Healthy Adults

Respiratory Syncytial Virus Infections | Parainfluenza Infections

United States
MedImmune LLC

Completed

Safety Study of a Monoclonal Antibody to Respiratory Syncytial Virus (RSV) in Children Hospitalized With RSV Infection

Respiratory Syncytial Virus Prophylaxis
MedImmune LLC

Completed

Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-524 in Healthy Adults

Respiratory Syncytial Virus Infections

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants

Healthy

United States, Australia, Spain, Germany, Canada, Finland, South Africa, Brazil, Israel
MedImmune LLC

Completed

Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of Age (CP149)

Respiratory Syncytial Virus Infections | Respiratory Viral Infections | Parainfluenza Virus 3, Human

United States
MedImmune LLC

Completed

Study of the Tumor Saturation and Biological Activity of MEDI-522 (Abergrin) in Patients With Advanced Malignant Melanoma

Malignant Melanoma

United States
MedImmune LLC

Completed

Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy Children

Healthy

United States
MedImmune LLC

Completed

Study of MEDI-522 Administered by Subcutaneous Injection to Adults With Plaque Psoriasis

Psoriasis

United States, Canada
MedImmune LLC

Completed

Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer

Cancer

United States
MedImmune LLC

Completed

A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease

Congenital Heart Disease

United States, Spain, United Kingdom, Canada, Belgium, Germany, Israel, Austria, Poland, Russian Federation, Sweden, Lebanon, France, Czech Republic, Hungary, Denmark, Bulgaria
MedImmune LLC

Completed

A Study to Evaluate the Efficacy of MEDI-528 on Late Asthmatic Response With Atopic Asthma

Asthma

Canada
MedImmune LLC

Completed

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Motavizumab (MEDI-524) After Dosing for a Second Season in Children

Motavizumab Administration for a Second Season for RSV Prophylaxis

Chile, Brazil
MedImmune LLC
AstraZeneca

Terminated

A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Mexico, Peru, South Africa, Canada
National Cancer Institute (NCI)

Terminated

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Shin Poong Pharmaceutical Co. Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of SP-8203

Ischemic Stroke

Korea, Republic of
University of California, San Diego

Recruiting

Mindfulness Engaged Neurostimulation for Depression (MEND)

Depressive Disorder | Depression | Major Depressive Disorder | Treatment Resistant Depression

United States
AstraZeneca
MedImmune LLC

Completed

A Study of MEDI-575 in Patients With Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
MedImmune LLC

Completed

Study of MEDI 507 in the Treatment of Pediatric Patients (Pediatric GvHD)

Graft Versus Host Disease

United States
AstraZeneca
MedImmune LLC

Terminated

Study to Assess MEDI -578 in Patients With Osteoarthritis (OA) of the Knee

Pain | Osteoarthritis

United Kingdom
MedImmune LLC

Completed

Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease

Cancer | Graft-Versus-Host Disease

United States
MedImmune LLC

Terminated

Study to Evaluate MEDI-507 in Patients With CD2-Positive Lymphoma/Leukemia

Lymphoma | Leukemia | Cancer

United States
MedImmune LLC

Completed

Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis, Relapsing Forms

United States, Spain, Poland, Ukraine
The Hospital for Sick Children
University of Calgary

Completed

Medi-Port Pilot Randomized Controlled Trial

Actively Undergoing Cancer Treatment | 4-9 Years of Age | At Least 1 Month From Diagnosis | Able to Speak and Understand English | Presenting to Clinic for at Least a 2nd Subcutaneous Port Needle Insertion

Canada
MedImmune LLC

Completed

A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

United States
MedImmune LLC

Completed

A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas

Gastrointestinal Adenocarcinomas

United States
MedImmune LLC

Terminated

Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors (MEDI-547)

Cancer

United States
MedImmune LLC

Completed

A Safety Clinical Trial of Different Doses of MEDI-507 in the Prevention of Acute Renal Allograft Rejection

Kidney Diseases

United States
MedImmune LLC

Terminated

Trial of MEDI-507 in CD2-Positive Lymphoproliferative Disease

Lymphoproliferative Disorders

United States
University of Calgary
Alberta Health services

Completed

MEDi Robot for Pain Management at Induction

Cognitive Therapy

Canada
MedImmune LLC

Terminated

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

RSV Infection

United Kingdom
University of Nottingham
University Hospitals of Derby and Burton NHS Foundation Trust

Completed

A Study of Agreement Between Oxygen Saturation Measured by Two Probes in Infants on the Neonatal Unit (Ag-OS)

Neonatal Disease

United Kingdom
MedImmune LLC

Completed

An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Mexico, Peru, Hungary, Ukraine, Czechia, Bulgaria, Colombia, Brazil, Poland, Romania, Taiwan
MedImmune LLC

Completed

A Phase 1, Single- and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MEDI4166 in Subjects With Type 2 Diabetes

Type 2 Diabetes

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma

Multiple Myeloma

United States
MedImmune LLC

Completed

A Study of the Safety and Tolerability of MEDI-551 in Scleroderma

Scleroderma

United States, United Kingdom, Canada
University of North Carolina, Chapel Hill
Med-El Corporation

Completed

Cochlear Implantation in Pediatric Cases of Unilateral Hearing Loss (CIPUHL)

Hearing Loss, Unilateral

United States
MedImmune LLC

Completed

Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma

Melanoma | Malignant Metastatic Melanoma

United States
Seoul National University Bundang Hospital
SAMJIN PHARM

Recruiting

Mobile App for Improving Adherence of Rivoxaban (RIVOX-AF)

Atrial Fibrillation

Korea, Republic of
AstraZeneca
Clinigen, Inc.

No longer available

Anifrolumab Early Access Program (AMANA)

Systemic Lupus Erythematosus
MedImmune LLC

Completed

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

Rheumatoid Arthritis

United States, Canada
Amgen
MedImmune LLC

Terminated

A Phase 1 Study of AMG 211 in Participants With Advanced Gastrointestinal Cancer

GI Adenocarcinoma

Germany, Netherlands

3

Subscribe